Bristol-Myers Squibb Company (BMY): A Bull Case Theory
We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Hennion & Walsh Asset Management Inc. Has $1.34 Million Position in Bristol-Myers Squibb (NYSE:BMY)
Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
The stock's rise snapped a three-day losing streak.
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
bovnews3d
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...